Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shugan Wendan Decoction plus Valsartan vs Valsartan alone for H-type essential hypertension
ChiCTR2000034557Phase 4Not yet recruiting
- Sponsor
- Guangdong Provincial Hospital of Traditional Chinese Medicine
- Start
- Jul 2020
- Countries
- 1
01
Overview
Phase 4, randomised trial of Shugan Wendan Tang in essential hypertension, hyperhomocysteinemia and hypertension (HTN) (2 arms), sponsored by Guangdong Provincial Hospital of Traditional Chinese Medicine. Primary endpoints: blood pressure and homocysteine. Planned start Jul 2020; status: not yet recruiting.
02
Drugs
Shugan Wendan Tang
03
Conditions
essential hypertensionhyperhomocysteinemiahypertension (HTN)
Beyond the preview
Go deeper on ChiCTR2000034557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000034557.